Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
501 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Obesity - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Obesity - Pipeline Review, H2 2014', provides an overview of the Obesity's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Obesity - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Obesity - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Obesity Overview 8 Therapeutics Development 9 Obesity - Therapeutics under Development by Companies 11 Obesity - Therapeutics under Investigation by Universities/Institutes 20 Obesity - Pipeline Products Glance 24 Obesity - Products under Development by Companies 27 Obesity - Products under Investigation by Universities/Institutes 39 Obesity - Companies Involved in Therapeutics Development 43 Obesity - Therapeutics Assessment 136 Drug Profiles 155 Obesity - Recent Pipeline Updates 417 Obesity - Dormant Projects 462 Obesity - Discontinued Products 466 Obesity - Product Development Milestones 468 Appendix 476
List of Tables Number of Products under Development for Obesity, H2 2014 33 Number of Products under Development for Obesity - Comparative Analysis, H2 2014 34 Number of Products under Development by Companies, H2 2014 36 Number of Products under Development by Companies, H2 2014 (Contd..1) 37 Number of Products under Development by Companies, H2 2014 (Contd..2) 38 Number of Products under Development by Companies, H2 2014 (Contd..3) 39 Number of Products under Development by Companies, H2 2014 (Contd..4) 40 Number of Products under Development by Companies, H2 2014 (Contd..5) 41 Number of Products under Development by Companies, H2 2014 (Contd..6) 42 Number of Products under Development by Companies, H2 2014 (Contd..7) 43 Number of Products under Investigation by Universities/Institutes, H2 2014 45 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 46 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 47 Comparative Analysis by Late Stage Development, H2 2014 48 Comparative Analysis by Clinical Stage Development, H2 2014 49 Comparative Analysis by Early Stage Development, H2 2014 50 Products under Development by Companies, H2 2014 51 Products under Development by Companies, H2 2014 (Contd..1) 52 Products under Development by Companies, H2 2014 (Contd..2) 53 Products under Development by Companies, H2 2014 (Contd..3) 54 Products under Development by Companies, H2 2014 (Contd..4) 55 Products under Development by Companies, H2 2014 (Contd..5) 56 Products under Development by Companies, H2 2014 (Contd..6) 57 Products under Development by Companies, H2 2014 (Contd..7) 58 Products under Development by Companies, H2 2014 (Contd..8) 59 Products under Development by Companies, H2 2014 (Contd..9) 60 Products under Development by Companies, H2 2014 (Contd..10) 61 Products under Development by Companies, H2 2014 (Contd..11) 62 Products under Investigation by Universities/Institutes, H2 2014 63 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 64 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 65 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 66 Obesity - Pipeline by Bristol-Myers Squibb Company, H2 2014 67 Obesity - Pipeline by Johnson & Johnson, H2 2014 68 Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 69 Obesity - Pipeline by Shionogi & Co., Ltd., H2 2014 70 Obesity - Pipeline by Amgen Inc., H2 2014 71 Obesity - Pipeline by Sanofi, H2 2014 72 Obesity - Pipeline by AstraZeneca PLC, H2 2014 73 Obesity - Pipeline by Eli Lilly and Company, H2 2014 74 Obesity - Pipeline by Athersys, Inc., H2 2014 75 Obesity - Pipeline by GlaxoSmithKline plc, H2 2014 76 Obesity - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 77 Obesity - Pipeline by Merck & Co., Inc., H2 2014 78 Obesity - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 79 Obesity - Pipeline by Euroscreen S.A., H2 2014 80 Obesity - Pipeline by Novo Nordisk A/S, H2 2014 81 Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 82 Obesity - Pipeline by Plexxikon Inc., H2 2014 83 Obesity - Pipeline by Ipsen S.A., H2 2014 84 Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 85 Obesity - Pipeline by GTx, Inc., H2 2014 86 Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 87 Obesity - Pipeline by LEO Pharma A/S, H2 2014 88 Obesity - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 89 Obesity - Pipeline by Pfizer Inc., H2 2014 90 Obesity - Pipeline by Vivus, Inc., H2 2014 91 Obesity - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 92 Obesity - Pipeline by OPKO Health, Inc., H2 2014 93 Obesity - Pipeline by Arrowhead Research Corporation, H2 2014 94 Obesity - Pipeline by Calzada Limited, H2 2014 95 Obesity - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H2 2014 96 Obesity - Pipeline by Arena Pharmaceuticals, Inc., H2 2014 97 Obesity - Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2014 98 Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014 99 Obesity - Pipeline by Xenetic Biosciences plc, H2 2014 100 Obesity - Pipeline by Handok Inc., H2 2014 101 Obesity - Pipeline by LG Life Sciences, Ltd., H2 2014 102 Obesity - Pipeline by Transition Therapeutics Inc., H2 2014 103 Obesity - Pipeline by Suven Life Sciences Ltd., H2 2014 104 Obesity - Pipeline by Galapagos NV, H2 2014 105 Obesity - Pipeline by CrystalGenomics, Inc., H2 2014 106 Obesity - Pipeline by Orexigen Therapeutics, Inc., H2 2014 107 Obesity - Pipeline by Digna Biotech, S.L., H2 2014 108 Obesity - Pipeline by Advinus Therapeutics Ltd., H2 2014 109 Obesity - Pipeline by Jenrin Discovery, Inc., H2 2014 110 Obesity - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 111 Obesity - Pipeline by ObeTherapy Biotechnology, H2 2014 112 Obesity - Pipeline by Helsinn Healthcare S.A., H2 2014 113 Obesity - Pipeline by AngioChem Inc., H2 2014 114 Obesity - Pipeline by Kedem Pharmaceuticals Inc., H2 2014 115 Obesity - Pipeline by Zafgen Inc., H2 2014 116 Obesity - Pipeline by Ambrx, Inc., H2 2014 117 Obesity - Pipeline by Braasch Biotech LLC, H2 2014 118 Obesity - Pipeline by Zealand Pharma A/S, H2 2014 119 Obesity - Pipeline by Intarcia Therapeutics, Inc., H2 2014 120 Obesity - Pipeline by Versartis, Inc., H2 2014 121 Obesity - Pipeline by Kainos Medicine, Inc., H2 2014 122 Obesity - Pipeline by Nordic Bioscience a/s, H2 2014 123 Obesity - Pipeline by Avaxia Biologics, Inc., H2 2014 124 Obesity - Pipeline by Omeros Corporation, H2 2014 125 Obesity - Pipeline by Aegis Therapeutics, LLC, H2 2014 126 Obesity - Pipeline by Bridge Bioresearch Plc, H2 2014 127 Obesity - Pipeline by Targacept, Inc., H2 2014 128 Obesity - Pipeline by Molecular Design International, Inc., H2 2014 129 Obesity - Pipeline by N-Gene Research Laboratories, Inc., H2 2014 130 Obesity - Pipeline by Seek, H2 2014 131 Obesity - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 132 Obesity - Pipeline by Galenea Corp., H2 2014 133 Obesity - Pipeline by Verva Pharmaceuticals Limited, H2 2014 134 Obesity - Pipeline by Regulus Therapeutics Inc., H2 2014 135 Obesity - Pipeline by Esperion Therapeutics, Inc., H2 2014 136 Obesity - Pipeline by Sorrento Therapeutics, Inc., H2 2014 137 Obesity - Pipeline by NGM Biopharmaceuticals, Inc., H2 2014 138 Obesity - Pipeline by Alize Pharma SAS, H2 2014 139 Obesity - Pipeline by DiscoveryBiomed, Inc., H2 2014 140 Obesity - Pipeline by Sirona Biochem Corp, H2 2014 141 Obesity - Pipeline by Vicore Pharma AB, H2 2014 142 Obesity - Pipeline by Carmot Therapeutics, Inc., H2 2014 143 Obesity - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 144 Obesity - Pipeline by PharmaIN Corporation, H2 2014 145 Obesity - Pipeline by Rhythm Pharmaceuticals, H2 2014 146 Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 147 Obesity - Pipeline by X-BODY BioSciences, Inc., H2 2014 148 Obesity - Pipeline by Lead Discovery Center GmbH, H2 2014 149 Obesity - Pipeline by AtheroNova Inc., H2 2014 150 Obesity - Pipeline by P2D Bioscience, H2 2014 151 Obesity - Pipeline by High Point Pharmaceuticals, LLC, H2 2014 152 Obesity - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 153 Obesity - Pipeline by Chronos Therapeutics Limited, H2 2014 154 Obesity - Pipeline by Kadmon Corporation, LLC, H2 2014 155 Obesity - Pipeline by nLife Therapeutics, S.L., H2 2014 156 Obesity - Pipeline by Orbis Biosciences, Inc., H2 2014 157 Obesity - Pipeline by XL-protein GmbH, H2 2014 158 Obesity - Pipeline by Akron Molecules AG, H2 2014 159 Assessment by Monotherapy Products, H2 2014 160 Assessment by Combination Products, H2 2014 161 Number of Products by Stage and Target, H2 2014 164 Number of Products by Stage and Mechanism of Action, H2 2014 170 Number of Products by Stage and Route of Administration, H2 2014 175 Number of Products by Stage and Molecule Type, H2 2014 178 Obesity Therapeutics - Recent Pipeline Updates, H2 2014 441 Obesity - Dormant Projects, H2 2014 486 Obesity - Discontinued Products, H2 2014 490
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
